← Back to Clinical Trials
Recruiting NCT06600646

Investigating the Role of ATP Production by Airway Epithelium in Patients With Refractory and Unexplained Chronic Cough (RCC/UCC).

Trial Parameters

Condition Chronic Cough (CC)
Sponsor McMaster University
Study Type OBSERVATIONAL
Phase N/A
Enrollment 30
Sex ALL
Min Age 18 Years
Max Age 80 Years
Start Date 2024-11-22
Completion 2025-10-01
Interventions
Bronchoscopy

Brief Summary

Chronic cough is a common troublesome symptom which has a global prevalence of approximately 10%, but with wide variations across continents. Patients with refractory and unexplained chronic cough (RCC/UCC) often exhibit dysregulated vagal pathways, necessitating a neuronal biomarker for targeted treatment. ATP, involved in the ATP/P2X3 pathway, may serve as a potential biomarker due to its role in the cough reflex. The study aims to discover if ATP production by the airway epithelium is greater in RCC/UCC patients compared with healthy controls, if the epithelium is a source of ATP, whether gene and protein expression related to ATP production differs between these groups and whether ATP release is triggered by mechanical and chemical stimulation. Additionally, the study seeks to determine if biomarker gene expression signatures can differentiate RCC/UCC patients from healthy controls.

Eligibility Criteria

Inclusion Criteria for RCC/UCC: * Patients with a history of RCC/UCC. * Normal Chest X-ray in the last 5 years. * No Evidence of Airflow Obstruction (FEV1/FVC ratio above LLN) * Cough Severity VAS ≥ 40 mm at screening. Inclusion Criteria for Healthy Controls: * No history of chronic cough, asthma, COPD, or clinical history of bronchiectasis or interstitial lung disease * No current smokers or those with \>10 pack year history. * No evidence of airflow obstruction ( FEV1/FVC ratio above LLN). * Able to understand and give written informed consent. Exclusion Criteria: * Participants who are currently established on treatment and their chronic cough is well controlled. * Unable to perform acceptable and reproducible spirometry. * Participants with a positive covid-19 test within 2 weeks of screening. * Current smoker or ex-smoker with ≥20 pack year smoking history and abstinence of ≤6 months * Symptoms of upper respiratory tract infection in the last 1 month which have not reso

Related Trials